KR20160061352A - 벤랄리주맙을 사용하여 만성 폐쇄성 폐 질환을 치료하는 방법 - Google Patents

벤랄리주맙을 사용하여 만성 폐쇄성 폐 질환을 치료하는 방법 Download PDF

Info

Publication number
KR20160061352A
KR20160061352A KR1020167009675A KR20167009675A KR20160061352A KR 20160061352 A KR20160061352 A KR 20160061352A KR 1020167009675 A KR1020167009675 A KR 1020167009675A KR 20167009675 A KR20167009675 A KR 20167009675A KR 20160061352 A KR20160061352 A KR 20160061352A
Authority
KR
South Korea
Prior art keywords
patient
copd
antigen
binding fragment
fev
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167009675A
Other languages
English (en)
Korean (ko)
Inventor
데르 멀리 르네 반
크리스틴 워드
위발도 마틴
로린 로스코스
빙 왕
Original Assignee
메디뮨 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 엘엘씨 filed Critical 메디뮨 엘엘씨
Publication of KR20160061352A publication Critical patent/KR20160061352A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167009675A 2013-10-15 2014-10-14 벤랄리주맙을 사용하여 만성 폐쇄성 폐 질환을 치료하는 방법 Ceased KR20160061352A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361891175P 2013-10-15 2013-10-15
US61/891,175 2013-10-15
US201461970126P 2014-03-25 2014-03-25
US61/970,126 2014-03-25
PCT/US2014/060432 WO2015057668A1 (en) 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab

Publications (1)

Publication Number Publication Date
KR20160061352A true KR20160061352A (ko) 2016-05-31

Family

ID=52809872

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167009675A Ceased KR20160061352A (ko) 2013-10-15 2014-10-14 벤랄리주맙을 사용하여 만성 폐쇄성 폐 질환을 치료하는 방법

Country Status (12)

Country Link
US (4) US20150104447A1 (enExample)
EP (2) EP3057609A4 (enExample)
JP (3) JP2016534996A (enExample)
KR (1) KR20160061352A (enExample)
CN (2) CN113230399A (enExample)
AU (2) AU2014334563A1 (enExample)
BR (1) BR112016008082A2 (enExample)
CA (1) CA2925402A1 (enExample)
MX (2) MX2016004329A (enExample)
RU (1) RU2706729C2 (enExample)
SG (2) SG10201807318RA (enExample)
WO (1) WO2015057668A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2992010B1 (en) 2013-04-29 2021-03-24 F.Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
SG10201800492PA (en) 2013-04-29 2018-03-28 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
BR112016014969A2 (pt) 2014-01-15 2018-01-23 Hoffmann La Roche polipeptídeo, formulação farmacêutica e uso de um polipeptídeo
JP6895884B2 (ja) 2015-06-01 2021-06-30 国立大学法人富山大学 肺高血圧症の治療薬及び治療方法
CN109544378B (zh) * 2018-10-27 2024-06-25 平安医疗健康管理股份有限公司 一种肺源性心脏病资质认证方法、设备及服务器
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
US20210230265A1 (en) * 2019-12-06 2021-07-29 Sanofi Biotechnology Methods for treating copd by administering an il-33 antagonist
EP3957308A1 (en) * 2020-08-21 2022-02-23 Palobiofarma, S.L. (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
WO2023034993A1 (en) * 2021-09-03 2023-03-09 Gleich Gerald J Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU690474B2 (en) * 1995-09-11 1998-04-23 Kyowa Hakko Kirin Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
PT1176195E (pt) * 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US7404953B2 (en) * 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20060014680A1 (en) * 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
DK3072525T3 (en) * 2007-05-14 2018-04-30 Astrazeneca Ab PROCEDURES FOR REDUCING BASOFILE CELL LEVELS
CN101249093A (zh) * 2008-03-19 2008-08-27 李虎山 一种治疗慢性阻塞性肺部疾病的组合物
CN103328506A (zh) * 2010-10-15 2013-09-25 米迪缪尼有限公司 用于改善肺功能的疗法
EP2652498B1 (en) * 2010-12-16 2018-04-18 F.Hoffmann-La Roche Ag Diagnosis and treatments relating to th2 inhibition
EP2710370A4 (en) * 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
JP2014533246A (ja) * 2011-11-01 2014-12-11 メディミューン，エルエルシー 喘息の急性増悪の頻度および重症度を低下させる方法
LT3033101T (lt) * 2013-08-12 2019-03-25 Astrazeneca Ab Astmos paūmejimo dažnio sumažinimo būdai naudojant benralizumabą
HUE043497T2 (hu) * 2013-08-12 2019-08-28 Astrazeneca Ab Módszerek a kényszerített kilégzési térfogat növelésére asztmásoknál benralizumab használatával
TR201910413T4 (tr) * 2013-08-12 2019-08-21 Astrazeneca Ab Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler.

Also Published As

Publication number Publication date
RU2706729C2 (ru) 2019-11-20
JP2016534996A (ja) 2016-11-10
US20150104447A1 (en) 2015-04-16
RU2016118425A3 (enExample) 2018-07-19
EP3057609A1 (en) 2016-08-24
CN105636607A (zh) 2016-06-01
RU2016118425A (ru) 2017-11-21
EP3057609A4 (en) 2017-03-22
JP6870037B2 (ja) 2021-05-12
SG10201807318RA (en) 2018-09-27
US20200123262A1 (en) 2020-04-23
CA2925402A1 (en) 2015-04-23
MX2016004329A (es) 2016-11-10
JP2019203009A (ja) 2019-11-28
WO2015057668A1 (en) 2015-04-23
SG11201601807XA (en) 2016-04-28
MX2019013468A (es) 2020-02-12
EP3485902A1 (en) 2019-05-22
AU2020202333A1 (en) 2020-04-23
US20170107291A1 (en) 2017-04-20
BR112016008082A2 (pt) 2017-10-17
AU2014334563A1 (en) 2016-04-07
US20180291108A1 (en) 2018-10-11
CN113230399A (zh) 2021-08-10
JP2021107421A (ja) 2021-07-29

Similar Documents

Publication Publication Date Title
JP6870037B2 (ja) ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法
KR20170072197A (ko) 중등증 내지 중증의 호산성 천식을 치료하기 위한 레슬리주맙의 용도
KR20160042123A (ko) 벤랄리주맙을 이용하여 천식 증상을 개선시키는 방법
Shioya et al. Effect of suplatast tosilate, a Th2 cytokine inhibitor, on cough variant asthma
Agbetile et al. New therapies and management strategies in the treatment of asthma: patient-focused developments
JP2025106329A (ja) ベンラリズマブを使用した強化された患者個体群における慢性閉塞性肺疾患を治療するための方法
JP2025527762A (ja) 抗インターロイキン－３３抗体を用いた喘息の治療
Saji et al. Efficacy of long-term omalizumab therapy in patients with severe asthma
HK40008332A (en) Methods for treating chronic obstructive pulmonary disease using benralizumab
US20230348606A1 (en) Methods for treating severe asthma in patients with nasal polyposis
US20210095037A1 (en) Methods for treating late-onset asthma using benralizumab
HK1224583A1 (en) Methods for treating chronic obstructive pulmonary disease using benralizumab
Davies The effect of Obstructive Sleep Apnoea (OSA) on health outcomes in patients with asthma: epidemiology, impact on asthma control, and effect of treatment using Continuous Positive Airway Pressure (CPAP)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160412

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20170206

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190723

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210216

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20211024

Patent event code: PE09021S02D

E601 Decision to refuse application
E801 Decision on dismissal of amendment
PE0601 Decision on rejection of patent

Patent event date: 20220727

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211024

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20210216

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

PE0801 Dismissal of amendment

Patent event code: PE08012E01D

Comment text: Decision on Dismissal of Amendment

Patent event date: 20220727

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20220224

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20210614